RAPT - CIK 0001673772
RAPT Therapeutics, Inc. trades as RAPT and has a market capitalization of $1.68 B, making it the #2237 largest US-listed company by market value. In its fiscal 2023 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$129.87M. This page tracks RAPT Therapeutics, Inc. through 569 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -1049.0% to -5490.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| 15-12G | - | 2026-03-18 |
| Insider trade | 4 | 2026-03-05 |
| Insider trade | 4 | 2026-03-05 |
| Insider trade | 4 | 2026-03-05 |
| Insider trade | 4 | 2026-03-05 |
| Insider trade | 4 | 2026-03-05 |
BRINGING NOVEL INVESTIGATIONAL TREATMENTS FOR ECZEMA, ASTHMA and cancer ONE STEP CLOSER TO APPROVAL
BRINGING NOVEL INVESTIGATIONAL TREATMENTS FOR ECZEMA, ASTHMA and cancer ONE STEP CLOSER TO APPROVAL
BRINGING NOVEL INVESTIGATIONAL TREATMENTS FOR ECZEMA, ASTHMA and cancer ONE STEP CLOSER TO APPROVAL
The largest companies sharing RAPT Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
RAPT Therapeutics, Inc. (RAPT) has a market capitalization of $1.68 B as of 2026-05-29, ranking #2237 among US-listed companies.
RAPT Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2023, a decrease of 100.0% year over year.
In its latest fiscal year RAPT Therapeutics, Inc. reported a net loss of $129.87M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.